NGNeurogene Inc. NGNE · NASDAQ
$24.28 -6.90% (-$1.80)
- Market cap
- $383.7M
- Enterprise value
- $279.5M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- -
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -53.7%
- Gross margin
- -
- Net margin
- -
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 2.09
- Free float
- 79.3%
About the company
Neurogene Inc. is an American biopharmaceutical company focused on the development of innovative therapies for the treatment of genetic neurological disorders. The company specializes in researching and developing gene therapy-based drugs that have the potential to treat and improve the lives of patients with genetically inherited neurological disorders.
Sector
Healthcare
Industry
Biotechnology
CEO
Rachel L. McMinn
Employees
131
Headquarters
New York City
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number